Telehealth abortion access faces legal challenge amid domestic violence concerns
Louisiana lawsuit challenges FDA rule allowing telehealth abortion pill access, raising concerns among domestic violence advocates who say remote care saves lives.
ATLANTA, GEORGIA — A federal lawsuit in Louisiana threatens to eliminate telehealth access to abortion medication, raising concerns among advocates who say the service provides a lifeline for domestic violence survivors seeking to escape abusive relationships.
Louisiana’s state government has filed suit against the U.S. Food and Drug Administration, challenging the agency’s 2023 rule that allows mifepristone to be dispensed without requiring an in-person medical visit. The medication is one of two drugs used to terminate pregnancies in the first trimester or treat miscarriages.
Domestic violence survivors say the telehealth option can mean the difference between life and death when leaving dangerous situations.
Personal Stories Highlight Stakes
Carrie Frail, a U.S. Air Force veteran living in Missouri, said telehealth abortion access could have been lifesaving during her own experience in 2008. Frail was attempting to leave an abusive relationship when she discovered she was pregnant.
“I firmly believe he would have killed me at some point, whether accidentally or intentionally,” Frail said. Her partner had threatened to hit her in the stomach until she miscarried, telling her it would save money.
Frail ultimately had a medication abortion at a Planned Parenthood clinic in St. Louis in 2008. She said the medication option allowed her to take less time off work and gave her the freedom to escape without providing her abuser with contact information.
“I was too wrapped up mentally and emotionally in my life with him that … I needed to be able to leave without giving him a phone number or letting him know where I was,” Frail said. “I still believe that an abortion saved my life.”
Another Survivor’s Experience
Kaelah Oberdorf, 24, had a medication abortion in 2023 while recovering from severe postpartum depression following the birth of her daughter. Oberdorf said she was in an emotionally abusive relationship at the time and didn’t want herself or her child to remain connected to that partner permanently.
Like Frail, Oberdorf’s story illustrates how reproductive healthcare access intersects with domestic violence situations, where victims may face additional barriers to seeking medical care.
Legal Challenge Could Restrict Access
The Louisiana lawsuit specifically targets the FDA’s 2023 regulatory change that expanded access to mifepristone through telehealth consultations. Prior to this rule, patients were required to obtain the medication through in-person medical visits only.
Researchers, advocates and domestic violence survivors argue that maintaining telehealth access remains essential for protecting vulnerable populations. For abuse victims, the ability to access reproductive healthcare remotely can provide safety and privacy that in-person visits might not offer.
The case highlights ongoing tensions over reproductive healthcare access and the role of federal agencies in regulating medical treatments. The outcome could affect how millions of women access abortion medication across the United States.
Mifepristone has been approved by the FDA for use in medication abortions since 2000. The drug is typically used in combination with misoprostol to terminate pregnancies up to 10 weeks of gestation and is also prescribed to treat incomplete miscarriages.
